TQ-B211

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQ-B211, covering 2020-05-13 to 2020-05-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. [Phase 3]

See pricing